- Home
- Publications
- Publication Search
- Publication Details
Title
Targeting cell-cycle machinery in cancer
Authors
Keywords
-
Journal
CANCER CELL
Volume -, Issue -, Pages -
Publisher
Elsevier BV
Online
2021-04-23
DOI
10.1016/j.ccell.2021.03.010
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study
- (2021) Erica L Mayer et al. LANCET ONCOLOGY
- Selective inhibition of Ph-positive ALL cell growth through kinase-dependent and independent effects by CDK6-specific PROTACs
- (2020) Marco De Dominici et al. BLOOD
- CDK4/6 Inhibitors Impair Recovery from Cytotoxic Chemotherapy in Pancreatic Adenocarcinoma
- (2020) Beatriz Salvador-Barbero et al. CANCER CELL
- Development of CDK2 and CDK5 Dual Degrader TMX‐2172
- (2020) Nathanael Schiander Gray et al. ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
- CDK7 inhibitors as anticancer drugs
- (2020) Georgina P. Sava et al. CANCER AND METASTASIS REVIEWS
- Mechanisms of Sensitivity and Resistance to CDK4/6 Inhibition
- (2020) Mónica Álvarez-Fernández et al. CANCER CELL
- Mammalian cell cycle cyclins
- (2020) Diego Martínez-Alonso et al. SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY
- The genomic landscape of intrinsic and acquired resistance to cyclin-dependent kinase 4/6 inhibitors in patients with hormone receptor positive metastatic breast cancer
- (2020) Seth A. Wander et al. Cancer Discovery
- A novel landscape of nuclear human CDK2 substrates revealed by in situ phosphorylation
- (2020) Yong Chi et al. Science Advances
- Pharmacogenomic Analysis Reveals CCNA2 as a Predictive Biomarker of Sensitivity to Polo-Like Kinase I Inhibitor in Gastric Cancer
- (2020) Yunji Lee et al. Cancers
- Targeted protein degradation as a powerful research tool in basic biology and drug target discovery
- (2020) Tao Wu et al. NATURE STRUCTURAL & MOLECULAR BIOLOGY
- Increased lysosomal biomass is responsible for the resistance of triple-negative breast cancers to CDK4/6 inhibition
- (2020) Anne Fassl et al. Science Advances
- The requirement for cyclin E in c-Myc overexpressing breast cancers
- (2020) Yu Zhou et al. CELL CYCLE
- Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2−, Node-Positive, High-Risk, Early Breast Cancer (monarchE)
- (2020) Stephen R. D. Johnston et al. JOURNAL OF CLINICAL ONCOLOGY
- Lysosomal trapping of palbociclib and its functional implications
- (2019) Susana Llanos et al. ONCOGENE
- Cyclin E1 Expression and Palbociclib Efficacy in Previously Treated Hormone Receptor–Positive Metastatic Breast Cancer
- (2019) Nicholas C. Turner et al. JOURNAL OF CLINICAL ONCOLOGY
- Selective Degradation of CDK6 by a Palbociclib Based PROTAC
- (2019) Sandeep Rana et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Development of Dual and Selective Degraders of Cyclin-Dependent Kinases 4 and 6
- (2019) Baishan Jiang et al. ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
- Molecular mechanism and potential target indication of TAK-931, a novel CDC7-selective inhibitor
- (2019) Kenichi Iwai et al. Science Advances
- Biomarker Analyses of Response to Cyclin Dependent Kinase 4/6 Inhibition and Endocrine Therapy in Women With Treatment-Naïve Metastatic Breast Cancer
- (2019) Richard S. Finn et al. CLINICAL CANCER RESEARCH
- Trilaciclib plus chemotherapy versus chemotherapy alone in patients with metastatic triple-negative breast cancer: a multicentre, randomised, open-label, phase 2 trial
- (2019) Antoinette R Tan et al. LANCET ONCOLOGY
- AZD4573 is a highly selective CDK9 inhibitor that suppresses Mcl-1 and induces apoptosis in hematological cancer cells.
- (2019) Justin Cidado et al. CLINICAL CANCER RESEARCH
- Inducing and exploiting vulnerabilities for the treatment of liver cancer
- (2019) Cun Wang et al. NATURE
- CDK7 Inhibition Potentiates Genome Instability Triggering Anti-tumor Immunity in Small Cell Lung Cancer
- (2019) Hua Zhang et al. CANCER CELL
- CDK4/6 inhibitor treatment for patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer: a US Food and Drug Administration pooled analysis
- (2019) Jennifer J Gao et al. LANCET ONCOLOGY
- CDK4/6 Inhibitors: The Mechanism of Action May Not Be as Simple as Once Thought
- (2018) Mary E. Klein et al. CANCER CELL
- Dinaciclib induces immunogenic cell death and enhances anti-PD1–mediated tumor suppression
- (2018) Dewan Md Sakib Hossain et al. JOURNAL OF CLINICAL INVESTIGATION
- ICEC0942, an Orally Bioavailable Selective Inhibitor of CDK7 for Cancer Treatment
- (2018) Hetal Patel et al. MOLECULAR CANCER THERAPEUTICS
- Targeting CDK2 overcomes melanoma resistance against BRAF and Hsp90 inhibitors
- (2018) Alireza Azimi et al. Molecular Systems Biology
- Combined BET bromodomain and CDK2 inhibition in MYC-driven medulloblastoma
- (2018) Sara Bolin et al. ONCOGENE
- Kinase-independent function of E-type cyclins in liver cancer
- (2018) Yan Geng et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- The CDK4/6 Inhibitor Abemaciclib Induces a T Cell Inflamed Tumor Microenvironment and Enhances the Efficacy of PD-L1 Checkpoint Blockade
- (2018) David A. Schaer et al. Cell Reports
- Low-Molecular-Weight Cyclin E in Human Cancer: Cellular Consequences and Opportunities for Targeted Therapies
- (2018) Joseph A. Caruso et al. CANCER RESEARCH
- Regulation of the initiation of DNA replication in human cells
- (2018) Tatiana N. Moiseeva et al. DNA REPAIR
- Cyclin E1 and cyclin-dependent kinase 2 are critical for initiation, but not for progression of hepatocellular carcinoma
- (2018) Roland Sonntag et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Targeting Cyclin-Dependent Kinases for Treatment of Gynecologic Cancers
- (2018) Z. Ping Lin et al. Frontiers in Oncology
- A Cancer Cell Program Promotes T Cell Exclusion and Resistance to Checkpoint Blockade
- (2018) Livnat Jerby-Arnon et al. CELL
- Phosphorylated RB Promotes Cancer Immunity by Inhibiting NF-κB Activation and PD-L1 Expression
- (2018) Xin Jin et al. MOLECULAR CELL
- NK cell–mediated cytotoxicity contributes to tumor control by a cytostatic drug combination
- (2018) Marcus Ruscetti et al. SCIENCE
- Cyclin A2/E1 activation defines a hepatocellular carcinoma subclass with a rearrangement signature of replication stress
- (2018) Quentin Bayard et al. Nature Communications
- MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2− Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy
- (2017) George W. Sledge et al. JOURNAL OF CLINICAL ONCOLOGY
- CDK4/6 inhibition triggers anti-tumour immunity
- (2017) Shom Goel et al. NATURE
- Cyclin D–CDK4 kinase destabilizes PD-L1 via cullin 3–SPOP to control cancer immune surveillance
- (2017) Jinfang Zhang et al. NATURE
- The metabolic function of cyclin D3–CDK6 kinase in cancer cell survival
- (2017) Haizhen Wang et al. NATURE
- ATRX is a regulator of therapy induced senescence in human cells
- (2017) Marta Kovatcheva et al. Nature Communications
- CDK4/6 Inhibition Augments Antitumor Immunity by Enhancing T-cell Activation
- (2017) Jiehui Deng et al. Cancer Discovery
- Synergistic effect of eribulin and CDK inhibition for the treatment of triple negative breast cancer
- (2017) Shreyas S. Rao et al. Oncotarget
- Stromal cyclin D1 promotes heterotypic immune signaling and breast cancer growth
- (2017) Timothy G. Pestell et al. Oncotarget
- Preclinical development of G1T38: A novel, potent and selective inhibitor of cyclin dependent kinases 4/6 for use as an oral antineoplastic in patients with CDK4/6 sensitive tumors
- (2017) John E. Bisi et al. Oncotarget
- Combined PI3K and CDK2 inhibition induces cell death and enhances in vivo antitumour activity in colorectal cancer
- (2016) Gary Beale et al. BRITISH JOURNAL OF CANCER
- Cyclin E Associates with the Lipogenic Enzyme ATP-Citrate Lyase to Enable Malignant Growth of Breast Cancer Cells
- (2016) Kimberly S. Lucenay et al. CANCER RESEARCH
- Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor–Positive Breast Cancer
- (2016) Maria Teresa Herrera-Abreu et al. CANCER RESEARCH
- Selective Targeting of Cyclin E1-Amplified High-Grade Serous Ovarian Cancer by Cyclin-Dependent Kinase 2 and AKT Inhibition
- (2016) George Au-Yeung et al. CLINICAL CANCER RESEARCH
- Sequential Combination Therapy of CDK Inhibition and Doxorubicin Is Synthetically Lethal in p53-Mutant Triple-Negative Breast Cancer
- (2016) N. A. Jabbour-Leung et al. MOLECULAR CANCER THERAPEUTICS
- Spectrum and Degree of CDK Drug Interactions Predicts Clinical Performance
- (2016) P. Chen et al. MOLECULAR CANCER THERAPEUTICS
- Treating cancer with selective CDK4/6 inhibitors
- (2016) Ben O'Leary et al. Nature Reviews Clinical Oncology
- Induced protein degradation: an emerging drug discovery paradigm
- (2016) Ashton C. Lai et al. NATURE REVIEWS DRUG DISCOVERY
- Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer
- (2016) Gabriel N. Hortobagyi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Palbociclib and Letrozole in Advanced Breast Cancer
- (2016) Richard S. Finn et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cyclin A2 is an RNA binding protein that controls Mre11 mRNA translation
- (2016) A. Kanakkanthara et al. SCIENCE
- Cyclin-Dependent Kinase 2 Promotes Tumor Proliferation and Induces Radio Resistance in Glioblastoma
- (2016) Jia Wang et al. Translational Oncology
- Metabolic Reprogramming of Pancreatic Cancer Mediated by CDK4/6 Inhibition Elicits Unique Vulnerabilities
- (2016) Jorge Franco et al. Cell Reports
- CDK7-Dependent Transcriptional Addiction in Triple-Negative Breast Cancer
- (2015) Yubao Wang et al. CELL
- Dual Inhibition of Cdc7 and Cdk9 by PHA-767491 Suppresses Hepatocarcinoma Synergistically with 5-Fluorouracil
- (2015) Wei Li et al. CURRENT CANCER DRUG TARGETS
- A phase 1 study with dose expansion of the CDK inhibitor dinaciclib (SCH 727965) in combination with epirubicin in patients with metastatic triple negative breast cancer
- (2015) Zahi Mitri et al. INVESTIGATIONAL NEW DRUGS
- The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study
- (2015) Richard S Finn et al. LANCET ONCOLOGY
- The history and future of targeting cyclin-dependent kinases in cancer therapy
- (2015) Uzma Asghar et al. NATURE REVIEWS DRUG DISCOVERY
- Cyclin-dependent kinase 2 is an ideal target for ovary tumors with elevated cyclin E1 expression
- (2015) Liu Yang et al. Oncotarget
- CDK1 Inhibition Targets the p53-NOXA-MCL1 Axis, Selectively Kills Embryonic Stem Cells, and Prevents Teratoma Formation
- (2015) Noelle E. Huskey et al. Stem Cell Reports
- Cyclin B1 Suppresses Colorectal Cancer Invasion and Metastasis by Regulating E-Cadherin
- (2015) Yifeng Fang et al. PLoS One
- Cdc7-Dbf4 Kinase Overexpression in Multiple Cancers and Tumor Cell Lines Is Correlated with p53 Inactivation
- (2015) Dorine Bonte et al. NEOPLASIA
- Targeting cyclin-dependent kinase 1 (CDK1) but not CDK4/6 or CDK2 is selectively lethal to MYC-dependent human breast cancer cells
- (2014) Jian Kang et al. BMC CANCER
- Targeting Transcriptional Addictions in Small Cell Lung Cancer with a Covalent CDK7 Inhibitor
- (2014) Camilla L. Christensen et al. CANCER CELL
- Loss of Cdk2 and Cyclin A2 Impairs Cell Proliferation and Tumorigenesis
- (2014) L. Gopinathan et al. CANCER RESEARCH
- CDK7 Inhibition Suppresses Super-Enhancer-Linked Oncogenic Transcription in MYCN-Driven Cancer
- (2014) Edmond Chipumuro et al. CELL
- Cyclin A2, a novel regulator of EMT
- (2014) Nawal Bendris et al. CELLULAR AND MOLECULAR LIFE SCIENCES
- Cyclin A2 and its associated kinase activity are required for optimal induction of progesterone receptor target genes in breast cancer cells
- (2014) Nicole L. Moore et al. JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY
- Targeting transcription regulation in cancer with a covalent CDK7 inhibitor
- (2014) Nicholas Kwiatkowski et al. NATURE
- Cell-cycle-regulated activation of Akt kinase by phosphorylation at its carboxyl terminus
- (2014) Pengda Liu et al. NATURE
- High expression of cyclin A is associated with poor prognosis in endometrial endometrioid adenocarcinoma
- (2014) Simi Santala et al. TUMOR BIOLOGY
- A Kinase-Independent Function of CDK6 Links the Cell Cycle to Tumor Angiogenesis
- (2013) Karoline Kollmann et al. CANCER CELL
- Cyclin E2 induces genomic instability by mechanisms distinct from cyclin E1
- (2013) C. Elizabeth Caldon et al. CELL CYCLE
- Randomized Phase II Trial of the Cyclin-Dependent Kinase Inhibitor Dinaciclib (MK-7965) Versus Capecitabine in Patients With Advanced Breast Cancer
- (2013) Monica M. Mita et al. Clinical Breast Cancer
- Resistance to CDK2 Inhibitors Is Associated with Selection of Polyploid Cells in CCNE1-Amplified Ovarian Cancer
- (2013) D. Etemadmoghadam et al. CLINICAL CANCER RESEARCH
- Foxp3 Protein Stability Is Regulated by Cyclin-dependent Kinase 2
- (2013) Peter A. Morawski et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- A first-in-human, phase 1, dose-escalation study of dinaciclib, a novel cyclin-dependent kinase inhibitor, administered weekly in subjects with advanced malignancies
- (2013) John J Nemunaitis et al. Journal of Translational Medicine
- Randomized phase 2 study of the cyclin-dependent kinase inhibitor dinaciclib (MK-7965) versus erlotinib in patients with non-small cell lung cancer
- (2013) Joe J. Stephenson et al. LUNG CANCER
- The Cancer Genome Atlas Pan-Cancer analysis project
- (2013) John N Weinstein et al. NATURE GENETICS
- The Anti-Melanoma Activity of Dinaciclib, a Cyclin-Dependent Kinase Inhibitor, Is Dependent on p53 Signaling
- (2013) Brijal M. Desai et al. PLoS One
- Discovery of XL413, a potent and selective CDC7 inhibitor
- (2012) Elena S. Koltun et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma
- (2012) J. P. Leonard et al. BLOOD
- The Requirement for Cyclin D Function in Tumor Maintenance
- (2012) Yoon Jong Choi et al. CANCER CELL
- A novel function for Cyclin A2: Control of cell invasion via RhoA signaling
- (2012) Nikola Arsic et al. JOURNAL OF CELL BIOLOGY
- MYC pathway activation in triple-negative breast cancer is synthetic lethal with CDK inhibition
- (2012) Dai Horiuchi et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Cyclin E2 Overexpression Is Associated with Endocrine Resistance but not Insensitivity to CDK2 Inhibition in Human Breast Cancer Cells
- (2012) C. E. Caldon et al. MOLECULAR CANCER THERAPEUTICS
- Chemical-genetic analysis of cyclin dependent kinase 2 function reveals an important role in cellular transformation by multiple oncogenic pathways
- (2012) D. Horiuchi et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Cyclin-dependent kinase 1 (Cdk1) is essential for cell division and suppression of DNA re-replication but not for liver regeneration
- (2012) M. K. Diril et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Cdk2 is Required for Breast Cancer Mediated by the Low-Molecular-Weight Isoform of Cyclin E
- (2011) S. Akli et al. CANCER RESEARCH
- Cyclin D1 and Cdk4 Mediate Development of Neurologically Destructive Oligodendroglioma
- (2011) D. Ciznadija et al. CANCER RESEARCH
- Mechanisms of Action of a Dual Cdc7/Cdk9 Kinase Inhibitor against Quiescent and Proliferating CLL Cells
- (2011) A. Natoni et al. MOLECULAR CANCER THERAPEUTICS
- Cyclin E amplification/overexpression is a mechanism of trastuzumab resistance in HER2+breast cancer patients
- (2011) Maurizio Scaltriti et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Targeting DNA Replication before it Starts
- (2010) Sara Rodriguez-Acebes et al. AMERICAN JOURNAL OF PATHOLOGY
- A Synthetic Lethal Interaction between K-Ras Oncogenes and Cdk4 Unveils a Therapeutic Strategy for Non-small Cell Lung Carcinoma
- (2010) Marta Puyol et al. CANCER CELL
- Targeting Cell Division Cycle 7 Kinase: A New Approach for Cancer Therapy
- (2010) A. Montagnoli et al. CLINICAL CANCER RESEARCH
- Dinaciclib (SCH 727965), a Novel and Potent Cyclin-Dependent Kinase Inhibitor
- (2010) David Parry et al. MOLECULAR CANCER THERAPEUTICS
- Amplicon-Dependent CCNE1 Expression Is Critical for Clonogenic Survival after Cisplatin Treatment and Is Correlated with 20q11 Gain in Ovarian Cancer
- (2010) Dariush Etemadmoghadam et al. PLoS One
- Pre-clinical evaluation of cyclin-dependent kinase 2 and 1 inhibition in anti-estrogen-sensitive and resistant breast cancer cells
- (2009) N Johnson et al. BRITISH JOURNAL OF CANCER
- Altered Subcellular Localization of Tumor-Specific Cyclin E Isoforms Affects Cyclin-Dependent Kinase 2 Complex Formation and Proteasomal Regulation
- (2009) N. A. Delk et al. CANCER RESEARCH
- The Development of a Selective Cyclin-Dependent Kinase Inhibitor That Shows Antitumor Activity
- (2009) S. Ali et al. CANCER RESEARCH
- Cyclin A Is Redundant in Fibroblasts but Essential in Hematopoietic and Embryonic Stem Cells
- (2009) Ilona Kalaszczynska et al. CELL
- Integrated Genome-Wide DNA Copy Number and Expression Analysis Identifies Distinct Mechanisms of Primary Chemoresistance in Ovarian Carcinomas
- (2009) D. Etemadmoghadam et al. CLINICAL CANCER RESEARCH
- Cdk2 suppresses cellular senescence induced by the c-myc oncogene
- (2009) Stefano Campaner et al. NATURE CELL BIOLOGY
- Healthy individuals have T-cell and antibody responses to the tumor antigen cyclin B1 that when elicited in mice protect from cancer
- (2009) L. A. Vella et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Inactivation of CDK2 is synthetically lethal to MYCN over-expressing cancer cells
- (2009) J. J. Molenaar et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Phosphorylation by Cdk2 is required for Myc to repress Ras-induced senescence in cotransformation
- (2009) P. Hydbring et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- A Cdc7 kinase inhibitor restricts initiation of DNA replication and has antitumor activity
- (2008) Alessia Montagnoli et al. Nature Chemical Biology
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now